NASDAQ:MACK - Merrimack Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$8.70 -0.06 (-0.68 %)
(As of 05/22/2018 05:35 AM ET)
Previous Close$8.76
Today's Range$8.57 - $8.82
52-Week Range$7.36 - $35.80
Volume52,841 shs
Average Volume140,103 shs
Market Capitalization$116.88 million
P/E Ratio-1.54
Dividend YieldN/A
Beta1.83

About Merrimack Pharmaceuticals (NASDAQ:MACK)

Merrimack Pharmaceuticals logoMerrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. The company's clinical programs include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive non-small cell lung cancer; and MM-141, a human tetravalent bispecific antibody that is in Phase II clinical trial for treating patients with metastatic pancreatic cancer with high serum levels of free insulin-like growth factor 1. Its clinical program also comprises MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to solid tumors. In addition, the company is developing preclinical product candidates for various solid tumor indications. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Receive MACK News and Ratings via Email

Sign-up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:MACK
CUSIP59032810
Phone617-441-1000

Debt

Debt-to-Equity RatioN/A
Current Ratio4.40
Quick Ratio4.40

Price-To-Earnings

Trailing P/E Ratio-1.54
Forward P/E Ratio-1.87
P/E GrowthN/A

Sales & Book Value

Annual Sales$144.27 million
Price / Sales0.80
Cash FlowN/A
Price / CashN/A
Book Value$7.22 per share
Price / Book1.20

Profitability

EPS (Most Recent Fiscal Year)($5.66)
Net Income$472.02 million
Net MarginsN/A
Return on Equity-64.89%
Return on Assets-40.80%

Miscellaneous

Employees72
Outstanding Shares13,340,000

Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?

Merrimack Pharmaceuticals shares reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals (NASDAQ:MACK) announced its quarterly earnings data on Monday, March, 12th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.27) by $0.38. View Merrimack Pharmaceuticals' Earnings History.

When is Merrimack Pharmaceuticals' next earnings date?

Merrimack Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Merrimack Pharmaceuticals.

What price target have analysts set for MACK?

1 brokers have issued 12 month price targets for Merrimack Pharmaceuticals' shares. Their predictions range from $12.00 to $12.00. On average, they anticipate Merrimack Pharmaceuticals' stock price to reach $12.00 in the next twelve months. View Analyst Ratings for Merrimack Pharmaceuticals.

Who are some of Merrimack Pharmaceuticals' key competitors?

Who are Merrimack Pharmaceuticals' key executives?

Merrimack Pharmaceuticals' management team includes the folowing people:
  • Dr. Ulrik B. Nielsen, Co-Founder & Director (Age 46)
  • Dr. Richard Peters, CEO, Pres & Director (Age 55)
  • Dr. Anthony J. Sinskey, Co-Founder and Scientific Advisor (Age 78)
  • Dr. Gavin MacBeath Ph.D., Founder
  • Ms. Jean M. Franchi, CFO & Treasurer (Age 52)

Has Merrimack Pharmaceuticals been receiving favorable news coverage?

Headlines about MACK stock have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Merrimack Pharmaceuticals earned a daily sentiment score of 0.14 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 47.13 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Merrimack Pharmaceuticals' major shareholders?

Merrimack Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.04%), FMR LLC (4.51%), Rubric Capital Management LP (3.57%), Dimensional Fund Advisors LP (2.77%), Northern Trust Corp (1.20%) and Newtyn Management LLC (1.06%). Company insiders that own Merrimack Pharmaceuticals stock include Birgit M Schoeberl, Daryl C Drummond and Ulrik B Nielsen. View Institutional Ownership Trends for Merrimack Pharmaceuticals.

Which institutional investors are selling Merrimack Pharmaceuticals stock?

MACK stock was sold by a variety of institutional investors in the last quarter, including Newtyn Management LLC, Millennium Management LLC, Yakira Capital Management Inc., Federated Investors Inc. PA and BlackRock Inc.. View Insider Buying and Selling for Merrimack Pharmaceuticals.

Which institutional investors are buying Merrimack Pharmaceuticals stock?

MACK stock was acquired by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Rubric Capital Management LP, Spark Investment Management LLC, Russell Investments Group Ltd. and Northern Trust Corp. View Insider Buying and Selling for Merrimack Pharmaceuticals.

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Merrimack Pharmaceuticals' stock price today?

One share of MACK stock can currently be purchased for approximately $8.70.

How big of a company is Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals has a market capitalization of $116.88 million and generates $144.27 million in revenue each year. The biopharmaceutical company earns $472.02 million in net income (profit) each year or ($5.66) on an earnings per share basis. Merrimack Pharmaceuticals employs 72 workers across the globe.

How can I contact Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals' mailing address is ONE KENDALL SQUARE SUITE B7201, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]


MarketBeat Community Rating for Merrimack Pharmaceuticals (MACK)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  263 (Vote Outperform)
Underperform Votes:  198 (Vote Underperform)
Total Votes:  461
MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe MACK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MACK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Merrimack Pharmaceuticals (NASDAQ:MACK) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Merrimack Pharmaceuticals in the last 12 months. Their average twelve-month price target is $12.00, suggesting that the stock has a possible upside of 37.93%. The high price target for MACK is $12.00 and the low price target for MACK is $12.00. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $12.00$12.00$15.00$15.00
Price Target Upside: 37.93% upside16.73% upside11.52% upside11.52% upside

Merrimack Pharmaceuticals (NASDAQ:MACK) Consensus Price Target History

Price Target History for Merrimack Pharmaceuticals (NASDAQ:MACK)

Merrimack Pharmaceuticals (NASDAQ:MACK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/15/2018Robert W. BairdReiterated RatingHold$12.00LowView Rating Details
5/19/2017CowenReiterated RatingMarket PerformLowView Rating Details
11/10/2016JPMorgan ChaseReiterated RatingHold$70.00N/AView Rating Details
11/10/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
8/5/2016Brean CapitalSet Price TargetBuy$160.00 ➝ $130.00N/AView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Merrimack Pharmaceuticals (NASDAQ:MACK) Earnings History and Estimates Chart

Earnings by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)

Merrimack Pharmaceuticals (NASDAQ:MACK) Earnings Estimates

Current Year EPS Consensus Estimate: $-4.66 EPS
Next Year EPS Consensus Estimate: $-3.98 EPS

Merrimack Pharmaceuticals (NASDAQ MACK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2018($1.30)N/AView Earnings Details
5/8/2018Q1 2018($1.28)($1.33)ViewN/AView Earnings Details
3/12/2018Q4 2017($1.27)($0.89)ViewN/AView Earnings Details
11/8/2017Q3 2017($1.88)($0.40)ViewN/AView Earnings Details
8/9/2017Q2 2017($1.37)($2.18)$18.00 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.70)($2.20)$32.16 millionViewN/AView Earnings Details
3/1/2017Q416($2.10)($2.50)$50.44 million$61.20 millionViewListenView Earnings Details
11/9/2016Q316($2.70)($2.30)$41.00 million$28.07 millionViewListenView Earnings Details
8/4/2016Q216($3.30)($4.00)$33.35 million$33.70 millionViewN/AView Earnings Details
5/2/2016Q116($3.80)($3.30)$24.16 million$21.30 millionViewN/AView Earnings Details
2/25/2016Q415($4.10)($4.10)$31.73 million$21.42 millionViewListenView Earnings Details
11/9/2015Q315($4.00)($3.80)$14.04 million$16.44 millionViewN/AView Earnings Details
8/10/2015Q215($3.10)($2.10)$17.57 million$36.60 millionViewListenView Earnings Details
5/7/2015Q1 2015($3.00)($3.20)$14.50 million$14.84 millionViewN/AView Earnings Details
2/26/2015Q4($2.30)($0.90)$25.13 million$33.91 millionViewN/AView Earnings Details
11/10/2014Q3 2014($1.20)($2.70)$61.50 million$28.00 millionViewN/AView Earnings Details
8/11/2014Q2 2014($3.20)($1.70)$10.83 million$27.82 millionViewN/AView Earnings Details
5/1/2014Q114($3.10)($2.70)$11.93 million$13.03 millionViewN/AView Earnings Details
2/27/2014($2.90)($3.30)$11.61 million$7.82 millionViewN/AView Earnings Details
11/7/2013($3.40)($3.90)$15.86 million$6.86 millionViewN/AView Earnings Details
8/8/2013Q2 2013($2.80)($3.10)$13.68 million$18.45 millionViewN/AView Earnings Details
5/13/2013Q1 2013($2.80)($2.90)$11.68 million$14.66 millionViewN/AView Earnings Details
3/14/2013Q4 2012($2.60)($17.60)$11.77 million$12.58 millionViewN/AView Earnings Details
11/14/2012Q312($18.10)$8.60 million$11.30 millionViewN/AView Earnings Details
8/10/2012Q2 2012($2.70)($2.21)ViewN/AView Earnings Details
5/15/2012Q1 2012($2.30)($21.40)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Merrimack Pharmaceuticals (NASDAQ:MACK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/7/2017Annual$10.605/30/20175/17/20175/26/2017
(Data available from 1/1/2013 forward)

Insider Trades

Merrimack Pharmaceuticals (NASDAQ MACK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.47%
Institutional Ownership Percentage: 56.91%
Insider Trading History for Merrimack Pharmaceuticals (NASDAQ:MACK)
Institutional Ownership by Quarter for Merrimack Pharmaceuticals (NASDAQ:MACK)

Merrimack Pharmaceuticals (NASDAQ MACK) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/15/2017Ulrik B NielsenDirectorSell7,896$14.23$112,360.0822,781View SEC Filing  
9/14/2017Ulrik B NielsenDirectorSell100$14.20$1,420.0022,781View SEC Filing  
9/13/2017Ulrik B NielsenDirectorSell21,556$14.40$310,406.4037,437View SEC Filing  
9/11/2017Ulrik B NielsenDirectorSell14,756$14.46$213,371.7637,437View SEC Filing  
5/12/2017Daryl C DrummondInsiderSell4,097$3.72$15,240.84View SEC Filing  
7/25/2016Birgit M SchoeberlInsiderSell50,000$5.50$275,000.00115,657View SEC Filing  
3/17/2016Michael E PorterDirectorBuy5,000$7.20$36,000.00754,448View SEC Filing  
3/15/2016Michael E PorterDirectorBuy5,000$7.65$38,250.00749,448View SEC Filing  
3/8/2016Michael E PorterDirectorBuy10,000$7.09$70,900.00744,448View SEC Filing  
3/3/2016Michael E PorterDirectorBuy15,000$6.39$95,850.00724,448View SEC Filing  
3/1/2016Michael E PorterDirectorBuy20,000$6.11$122,200.00709,448View SEC Filing  
2/29/2016Vivian S LeeDirectorBuy35,000$5.50$192,500.0065,000View SEC Filing  
2/29/2016William M McclementsInsiderBuy2,000$5.72$11,440.0014,072View SEC Filing  
1/5/2016Edward J. StewartinsiderSell4,000$8.00$32,000.0021,385View SEC Filing  
12/1/2015Edward J. StewartinsiderSell5,000$9.33$46,650.0021,385View SEC Filing  
11/2/2015Edward J. StewartinsiderSell6,000$9.42$56,520.0021,385View SEC Filing  
10/16/2015Edward J. StewartinsiderSell1,000$10.00$10,000.0021,385View SEC Filing  
10/2/2015Edward J. StewartinsiderSell5,000$8.20$41,000.0021,385View SEC Filing  
9/1/2015Edward J. StewartinsiderSell6,000$9.88$59,280.0021,385View SEC Filing  
8/21/2015Michael E PorterDirectorBuy5,000$9.76$48,800.00699,448View SEC Filing  
8/17/2015Edward J. StewartinsiderSell6,000$10.49$62,940.0021,385View SEC Filing  
8/14/2015Michael E PorterDirectorBuy13,000$10.54$137,020.00View SEC Filing  
7/20/2015Ulrik B NielsenDirectorSell20,000$10.71$214,200.00View SEC Filing  
7/15/2015Edward J StewartInsiderSell6,000$11.84$71,040.00View SEC Filing  
7/15/2015William A SullivanCFOSell15,000$11.85$177,750.00View SEC Filing  
6/19/2015Ulrik B NielsenDirectorSell40,000$12.02$480,800.00View SEC Filing  
6/18/2015Edward J StewartInsiderSell2,000$12.00$24,000.00View SEC Filing  
6/15/2015Edward J StewartInsiderSell6,000$10.67$64,020.00View SEC Filing  
6/15/2015William A SullivanCFOSell15,000$10.65$159,750.00View SEC Filing  
5/19/2015Ulrik B NielsenDirectorSell40,000$13.04$521,600.00View SEC Filing  
5/13/2015Michael E PorterDirectorBuy8,284$11.79$97,668.36View SEC Filing  
4/20/2015Ulrik B NielsenDirectorSell40,000$12.88$515,200.00View SEC Filing  
4/15/2015Edward J StewartSVPSell8,000$12.79$102,320.00View SEC Filing  
4/15/2015William A SullivanCFOSell15,000$12.87$193,050.00View SEC Filing  
4/13/2015Gordon J FehrDirectorSell20,000$13.00$260,000.00View SEC Filing  
3/24/2015Robert J MulroyCEOSell114,368$11.71$1,339,249.28View SEC Filing  
3/23/2015Robert J MulroyCEOSell10,400$11.69$121,576.00View SEC Filing  
3/20/2015Michael E PorterDirectorBuy5,000$11.77$58,850.00View SEC Filing  
3/19/2015Ulrik B NielsenDirectorSell40,000$11.97$478,800.00View SEC Filing  
3/19/2015William A SullivanCFOSell15,000$11.97$179,550.00View SEC Filing  
3/17/2015Birgit M SchoeberlInsiderSell42,234$12.00$506,808.00View SEC Filing  
3/17/2015Edward J StewartSVPSell8,000$11.95$95,600.00View SEC Filing  
3/17/2015Michael E PorterDirectorBuy1,190$11.77$14,006.30View SEC Filing  
3/16/2015Birgit M SchoeberlInsiderSell20,897$12.00$250,764.00View SEC Filing  
3/16/2015Edward J StewartSVPSell6,000$11.93$71,580.00View SEC Filing  
3/11/2015Michael E PorterDirectorBuy5,000$11.33$56,650.00View SEC Filing  
3/2/2015Michael E PorterDirectorBuy5,000$10.93$54,650.00View SEC Filing  
2/23/2015Ulrik B NielsenDirectorSell20,000$10.91$218,200.00View SEC Filing  
2/20/2015Robert J MulroyCEOSell150,000$10.94$1,641,000.00View SEC Filing  
1/15/2015Edward J StewartSVPSell6,000$11.19$67,140.00View SEC Filing  
12/24/2014William A SullivanCFOSell15,000$10.70$160,500.00View SEC Filing  
12/23/2014Vivian S LeeDirectorBuy20,000$10.23$204,600.00View SEC Filing  
12/18/2014Anthony J SinskeyDirectorSell20,000$10.31$206,200.00View SEC Filing  
12/15/2014Edward J StewartSVPSell6,000$10.63$63,780.00View SEC Filing  
12/8/2014Robert J MulroyCEOSell200,000$9.84$1,968,000.00View SEC Filing  
12/2/2014Michael E PorterDirectorBuy8,000$8.71$69,680.00View SEC Filing  
11/21/2014Michael E PorterDirectorBuy11,909$8.87$105,632.83View SEC Filing  
11/18/2014Edward J StewartSVPSell5,000$8.55$42,750.00View SEC Filing  
11/14/2014Michael E PorterDirectorBuy5,000$8.29$41,450.00View SEC Filing  
11/13/2014Gary L CrockerDirectorBuy14,390$8.47$121,883.30View SEC Filing  
11/12/2014Michael E PorterDirectorBuy40,000$8.37$334,800.00View SEC Filing  
10/23/2014Edward J StewartSVPSell3,000$9.05$27,150.00View SEC Filing  
9/30/2014William A SullivanCFOSell105,282$8.61$906,478.02View SEC Filing  
9/29/2014William A SullivanCFOSell64,404$8.40$540,993.60View SEC Filing  
9/24/2014Edward J StewartSVPSell12,000$8.22$98,640.00View SEC Filing  
6/23/2014Gary L CrockerDirectorBuy36,000$6.84$246,240.00View SEC Filing  
5/20/2014Gary CrockerDirectorBuy4,000$6.69$26,760.002,808,571View SEC Filing  
5/19/2014Gary CrockerDirectorBuy9,400$6.68$62,792.002,804,571View SEC Filing  
5/16/2014Michael PorterDirectorBuy15,000$6.49$97,350.00535,865View SEC Filing  
5/13/2014Anthony SinskeyDirectorBuy5,000$6.74$33,700.00View SEC Filing  
5/8/2014Michael PorterDirectorBuy10,000$6.59$65,900.00520,865View SEC Filing  
5/7/2014Gary CrockerDirectorBuy4,400$6.77$29,788.00View SEC Filing  
5/6/2014Gary CrockerDirectorBuy17,500$6.89$120,575.002,783,271View SEC Filing  
5/5/2014Michael PorterDirectorBuy15,000$6.41$96,150.00485,865View SEC Filing  
5/5/2014Robert MulroyCEOBuy5,000$6.31$31,550.00946,069View SEC Filing  
12/17/2013Michael PorterDirectorBuy25,000$4.75$118,750.00470,865View SEC Filing  
12/12/2013William McclementsSVPBuy4,000$4.26$17,040.0013,000View SEC Filing  
12/10/2013Michael PorterDirectorBuy18,000$4.38$78,840.00445,865View SEC Filing  
12/6/2013James QuigleyDirectorBuy39,000$4.70$183,300.0051,500View SEC Filing  
12/4/2013Robert MulroyCEOBuy33,100$4.42$146,302.00989,644View SEC Filing  
12/3/2013Sarah NashDirectorBuy47,500$4.17$198,075.00976,994View SEC Filing  
12/2/2013William McclementsSVPBuy2,000$4.06$8,120.009,000View SEC Filing  
11/29/2013Anthony SinskeyDirectorBuy3,800$3.92$14,896.00392,543View SEC Filing  
11/27/2013Gary CrockerDirectorBuy207,000$3.72$770,040.00View SEC Filing  
12/14/2012John MendelsohnDirectorBuy5,000$6.63$33,150.00View SEC Filing  
12/13/2012Gary L CrockerDirectorBuy36,500$6.77$247,105.00View SEC Filing  
12/10/2012Michael E PorterDirectorBuy10,000$6.08$60,800.00View SEC Filing  
9/14/2012Gary L CrockerDirectorBuy64,800$8.33$539,784.00View SEC Filing  
8/24/2012James H QuigleyDirectorBuy12,500$7.55$94,375.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Merrimack Pharmaceuticals (NASDAQ MACK) News Headlines

Source:
DateHeadline
Merrimack Pharmaceuticals (MACK) Lowered to "Hold" at Zacks Investment ResearchMerrimack Pharmaceuticals (MACK) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 15 at 1:13 PM
Edited Transcript of MACK earnings conference call or presentation 8-May-18 12:30pm GMTEdited Transcript of MACK earnings conference call or presentation 8-May-18 12:30pm GMT
finance.yahoo.com - May 11 at 8:28 AM
Investors Purchase High Volume of Merrimack Pharmaceuticals Call Options (MACK)Investors Purchase High Volume of Merrimack Pharmaceuticals Call Options (MACK)
www.americanbankingnews.com - May 10 at 8:02 AM
Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1
finance.yahoo.com - May 9 at 5:33 PM
Merrimack Pharmaceuticals (MACK) Announces Quarterly  Earnings Results, Misses Expectations By $0.05 EPSMerrimack Pharmaceuticals (MACK) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - May 9 at 4:21 PM
Merrimack Pharmaceuticals (MACK) CEO Richard Peters on Q1 2018 Results - Earnings Call TranscriptMerrimack Pharmaceuticals' (MACK) CEO Richard Peters on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 5:39 PM
BRIEF-Merrimack Pharmaceuticals Reports Q1 Operating Loss Per Share Of $1.33BRIEF-Merrimack Pharmaceuticals Reports Q1 Operating Loss Per Share Of $1.33
www.reuters.com - May 8 at 8:16 AM
Merrimack Reports First Quarter 2018 Financial ResultsMerrimack Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 8 at 8:16 AM
Merrimack (MACK) Reports Wider-than-Expected Q1 LossMerrimack (MACK) Reports Wider-than-Expected Q1 Loss
finance.yahoo.com - May 8 at 8:16 AM
Merrimack Pharmaceuticals (MACK) Downgraded by Zacks Investment Research to "Hold"Merrimack Pharmaceuticals (MACK) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - May 3 at 11:44 PM
What's in the Cards for Merrimack (MACK) in Q1 Earnings?What's in the Cards for Merrimack (MACK) in Q1 Earnings?
finance.yahoo.com - May 3 at 5:24 PM
Merrimack Pharmaceuticals (MACK) Rating Increased to Buy at Zacks Investment ResearchMerrimack Pharmaceuticals (MACK) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - May 2 at 12:25 PM
Merrimack Announces Timing of First Quarter 2018 Investor Conference CallMerrimack Announces Timing of First Quarter 2018 Investor Conference Call
finance.yahoo.com - May 1 at 8:26 AM
Merrimack Pharmaceuticals (MACK) to Release Quarterly Earnings on TuesdayMerrimack Pharmaceuticals (MACK) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 1 at 7:12 AM
-$1.28 Earnings Per Share Expected for Merrimack Pharmaceuticals (MACK) This Quarter-$1.28 Earnings Per Share Expected for Merrimack Pharmaceuticals (MACK) This Quarter
www.americanbankingnews.com - April 30 at 5:14 PM
Merrimack Pharmaceuticals (MACK) Stock Rating Upgraded by Zacks Investment ResearchMerrimack Pharmaceuticals (MACK) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 25 at 1:30 PM
Merrimack Pharmaceuticals Potential Catalyst A Likely BustMerrimack Pharmaceuticals Potential Catalyst A Likely Bust
seekingalpha.com - April 19 at 5:40 PM
Zacks: Analysts Anticipate Merrimack Pharmaceuticals (MACK) to Announce -$1.28 EPSZacks: Analysts Anticipate Merrimack Pharmaceuticals (MACK) to Announce -$1.28 EPS
www.americanbankingnews.com - April 13 at 7:15 PM
Merrimack Pharma (MACK) to Present Preclinical Data at AACR MeetingMerrimack Pharma (MACK) to Present Preclinical Data at AACR Meeting
www.streetinsider.com - April 10 at 8:27 AM
Merrimack to Present Preclinical Data at the 2018 American Association for Cancer Research Annual MeetingMerrimack to Present Preclinical Data at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 9 at 8:19 AM
ValuEngine Downgrades Merrimack Pharmaceuticals (MACK) to Strong SellValuEngine Downgrades Merrimack Pharmaceuticals (MACK) to Strong Sell
www.americanbankingnews.com - April 8 at 11:48 AM
Merrimack Pharmaceuticals (MACK) Downgraded to Sell at Zacks Investment ResearchMerrimack Pharmaceuticals (MACK) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - April 7 at 4:58 PM
Consolidated Research: 2018 Summary Expectations for Merrimack Pharmaceuticals, Monroe Capital, NL Industries, FCB Financial, Amtech, and Otter Tail — Fundamental Analysis, Key Performance IndicationsConsolidated Research: 2018 Summary Expectations for Merrimack Pharmaceuticals, Monroe Capital, NL Industries, FCB Financial, Amtech, and Otter Tail — Fundamental Analysis, Key Performance Indications
finance.yahoo.com - April 4 at 8:21 AM
Zacks: Analysts Anticipate Merrimack Pharmaceuticals Inc (MACK) to Announce -$1.28 EPSZacks: Analysts Anticipate Merrimack Pharmaceuticals Inc (MACK) to Announce -$1.28 EPS
www.americanbankingnews.com - March 27 at 7:18 PM
Merrimack Pharmaceuticals (MACK) Earns Hold Rating from Robert W. BairdMerrimack Pharmaceuticals (MACK) Earns Hold Rating from Robert W. Baird
www.americanbankingnews.com - March 15 at 3:02 PM
Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4 - NasdaqMerrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4 - Nasdaq
www.nasdaq.com - March 14 at 8:33 AM
Merrimack Provides Business Update and Reports 2017 Financial Results - PR Newswire (press release)Merrimack Provides Business Update and Reports 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - March 13 at 8:26 AM
BRIEF-Merrimack Strengthens SHERLOC Study Of MM-121 In Non-Small Cell Lung CancerBRIEF-Merrimack Strengthens SHERLOC Study Of MM-121 In Non-Small Cell Lung Cancer
www.reuters.com - March 12 at 9:15 AM
Merrimack Provides Business Update and Reports 2017 Financial ResultsMerrimack Provides Business Update and Reports 2017 Financial Results
finance.yahoo.com - March 12 at 9:15 AM
Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung CancerMerrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer
finance.yahoo.com - March 12 at 9:15 AM
 Brokerages Anticipate Merrimack Pharmaceuticals Inc (MACK) Will Post Quarterly Sales of $33.00 Million Brokerages Anticipate Merrimack Pharmaceuticals Inc (MACK) Will Post Quarterly Sales of $33.00 Million
www.americanbankingnews.com - March 12 at 5:22 AM
Reviewing Merrimack Pharmaceuticals (MACK) and GenVec (GNVC)Reviewing Merrimack Pharmaceuticals (MACK) and GenVec (GNVC)
www.americanbankingnews.com - March 11 at 5:28 PM
Merrimack Pharmaceuticals (MACK) Scheduled to Post Earnings on MondayMerrimack Pharmaceuticals (MACK) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - March 6 at 8:18 PM
Merrimack Announces Timing of Full Year 2017 Investor Conference Call and Presentation at the Cowen Health Care ... - PR Newswire (press release)Merrimack Announces Timing of Full Year 2017 Investor Conference Call and Presentation at the Cowen Health Care ... - PR Newswire (press release)
www.prnewswire.com - March 5 at 8:18 AM
Merrimack Announces Timing of Full Year 2017 Investor Conference Call and Presentation at the Cowen Health Care ConferenceMerrimack Announces Timing of Full Year 2017 Investor Conference Call and Presentation at the Cowen Health Care Conference
finance.yahoo.com - March 5 at 8:18 AM
Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal ... - PR Newswire (press release)Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal ... - PR Newswire (press release)
www.prnewswire.com - February 27 at 8:19 AM
Are Earnings Prospects Improving For Loss-Making Merrimack Pharmaceuticals Inc’s (NASDAQ:MACK)?Are Earnings Prospects Improving For Loss-Making Merrimack Pharmaceuticals Inc’s (NASDAQ:MACK)?
finance.yahoo.com - February 27 at 8:19 AM
BRIEF-Merrimack Says Dosed First Patient In Randomized Phase 2 Clinical Study Of MM-121BRIEF-Merrimack Says Dosed First Patient In Randomized Phase 2 Clinical Study Of MM-121
www.reuters.com - February 26 at 5:44 PM
Merrimack Pharma (MACK) Reports Dosing 1st Patient in Randomized Phase 2 Clinical Study of MM-121 - StreetInsider.comMerrimack Pharma (MACK) Reports Dosing 1st Patient in Randomized Phase 2 Clinical Study of MM-121 - StreetInsider.com
www.streetinsider.com - February 26 at 8:17 AM
Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast CancerMerrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast Cancer
finance.yahoo.com - February 26 at 8:17 AM
Whats in the Cards for Merrimack (MACK) in Q4 Earnings? - NasdaqWhat's in the Cards for Merrimack (MACK) in Q4 Earnings? - Nasdaq
www.nasdaq.com - February 24 at 8:16 AM
Whats in the Cards for Merrimack (MACK) in Q4 Earnings?What's in the Cards for Merrimack (MACK) in Q4 Earnings?
www.msn.com - February 23 at 5:58 PM
What's in the Cards for Merrimack (MACK) in Q4 Earnings?What's in the Cards for Merrimack (MACK) in Q4 Earnings?
finance.yahoo.com - February 23 at 5:58 PM
Zacks: Brokerages Anticipate Merrimack Pharmaceuticals Inc (MACK) to Post -$0.28 EPSZacks: Brokerages Anticipate Merrimack Pharmaceuticals Inc (MACK) to Post -$0.28 EPS
www.americanbankingnews.com - February 21 at 7:10 PM
Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology - PR Newswire (press release)Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology - PR Newswire (press release)
www.prnewswire.com - February 20 at 8:17 AM
Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision OncologyMerrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology
finance.yahoo.com - February 20 at 8:17 AM
Merrimack Pharmaceuticals (MACK) to Release Earnings on TuesdayMerrimack Pharmaceuticals (MACK) to Release Earnings on Tuesday
www.americanbankingnews.com - February 20 at 4:12 AM
Merrimack to Present at the 2018 RBC Capital Markets Global Healthcare ConferenceMerrimack to Present at the 2018 RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 15 at 9:19 AM
Merrimack Pharmaceuticals Inc (MACK) Expected to Post Quarterly Sales of $33.00 MillionMerrimack Pharmaceuticals Inc (MACK) Expected to Post Quarterly Sales of $33.00 Million
www.americanbankingnews.com - February 6 at 3:52 AM
Zacks: Brokerages Anticipate Merrimack Pharmaceuticals Inc (MACK) Will Post Earnings of -$0.28 Per ShareZacks: Brokerages Anticipate Merrimack Pharmaceuticals Inc (MACK) Will Post Earnings of -$0.28 Per Share
www.americanbankingnews.com - February 4 at 7:08 PM

SEC Filings

Merrimack Pharmaceuticals (NASDAQ:MACK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Merrimack Pharmaceuticals (NASDAQ:MACK) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Merrimack Pharmaceuticals (NASDAQ MACK) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.